

## Regimen Reference Order – THOR – entrectinib

ARIA: LUNG – [entrectinib]

**Planned Course:** Once daily until disease progression or unacceptable toxicity  
(1 cycle = 30 days)

**Indication for Use:** Non-Small Cell Lung Cancer ROS1-Positive Locally Advanced or Metastatic

### **Proceed with treatment if:**

- *ANC equal to or greater than  $1 \times 10^9/L$  AND Platelets equal to or greater than  $100 \times 10^9/L$*
- *AST/ALT equal to or less than 5 times the upper limit of normal*
- *Total bilirubin equal to or less than 1.5 times the upper limit of normal*
- *Uric acid equal to or less than the upper limit of normal*
- ❖ **Contact Physician if parameters not met**

### Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

### Treatment Regimen – THOR – entrectinib

Drug	Dose	CCMB Administration Guideline
entrectinib	600 mg	Orally once daily with or without food Swallow whole (Self-administered at home)
entrectinib (Rozlytrek®) available dosage strengths: 100 mg and 200 mg capsules Classification: Cytotoxic, Hazardous		

## REQUIRED MONITORING

### Cycle 1

#### Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid and albumin as per Physician Orders
- EKG
- LVEF monitoring is not required at baseline. If clinically indicated, cardiac investigations will occur at prescriber's discretion

#### Day 15

- CBC, liver enzymes, total bilirubin and uric acid as per Physician Orders

### Cycle 2

#### Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid and albumin as per Physician Orders
- EKG

**Cycle 3****Day 1**

- CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid and albumin as per Physician Orders
- EKG as clinically indicated to assess for atrial fibrillation at prescriber's discretion

**Cycle 4 and Onwards**

- CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid and albumin
  - At the physician's discretion but no less than every 3 months
- EKG as clinically indicated to assess for atrial fibrillation at prescriber's discretion

<b>Recommended Support Medications</b>		
<b>Drug</b>	<b>Dose</b>	<b>CCMB Administration Guideline</b>
None required		

**DISCHARGE INSTRUCTIONS**

- entrectinib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Patients should be counseled on potential for vision changes and cognitive changes with entrectinib
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on entrectinib

**ADDITIONAL INFORMATION**

- entrectinib can cause hyperuricemia
- entrectinib can prolong QT interval
- entrectinib will be dispensed by CCMB pharmacy